Table 4 Outcomes, instruments used, and effects of decisions aids evaluated in the included one-group pretest-posttest design study

 Decisional conflict

Decisional Conflict Scale^a

Metcalfe 2007 [27]

Pre-test 36.2 (16.4), Post-test 23.0 (15.2)

Significantly less decisional conflict after using the DA.

 Strenght of treatment preference

15-point scale

Metcalfe 2007 [27]

RR-M:

Significantly fewer women in the DA group were uncertain about RR-M and RR-O.

Pre-test No 14, Yes 3, Unsure 3

Post-test No 10, Yes 4, Unsure 6

RR-O:

Pre-test No 5, Yes 12, Unsure 3

Post-test No 2, Yes 15, Unsure 3

Tamoxifen:

Pre-test No 10, Yes 1, Unsure 9

Post-test No 11, Yes 5, Unsure 4

 Risk perception

BC risk, mutation carriers^b

Metcalfe 2007 [27]

Pre-test 65.1 (16.1), Post-test 73.6 (13.4)

Significantly better risk perception after using the DA.

BC, risk after RR-M, mutation carriers^b

Metcalfe 2007 [27]

Pre-test 71.8 (22.0), Post-test 84.2 (18.2)

Significantly better risk perception after using the DA.

BC, risk after RR-O, mutation carriers^b

Metcalfe 2007 [27]

Pre-test 43.2 (20.0), Post-test 65.0 (13.3)

Significantly better risk perception after using the DA.

BC, risk with Tamoxifen, mutation carriers^b

Metcalfe 2007 [27]

Pre-test 50.0 (19.0), Post-test 56.6 (10.0)

No significant difference.

BC, risk with mammography, mutation carriers^b

Metcalfe 2007 [27]

Pre-test 21.5 (28.0), Post-test 13.5 (22.8)

No significant difference.

 Distress

Impact of Event Scale^a

Metcalfe 2007 [27]

Pre-test 22.7 (13.7), Post-test 19.9 (14.5)

No significant difference.